The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1424
September 2, 2013
View Complete Issue         Table of Contents 2019 
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD
September 2, 2013 (Issue: 1424)
The FDA has approved an inhaled fixed-dose combination (Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta2-adrenergic agonist (LABA) vilanterol trifenatate for once-daily treatment of chronic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD
Article code: 1424a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.